| Synonyms: | |
| Status: | Approved (2003) Withdrawn (2009) |
| Entry Type: | Antibody |
| Molecule Category: | UNKNOWN |
| ATC: | L04AA21 |
| UNII: | XX2MN88N5D |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| INHIBITOR | Integrin alpha-L/beta-2 (LFA-1) inhibitor | FDA |
| Primary Target | |
|---|---|
| integrin, alpha L subunit (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Psoriasis | 3 | D011565 | ClinicalTrials |
| Alopecia | 2 | D000505 | ClinicalTrials |
| Sjogren's Syndrome | 2 | D012859 | ClinicalTrials |
| Arthritis, Rheumatoid | 2 | D001172 | ClinicalTrials |
| Dermatitis, Atopic | 2 | D003876 | ClinicalTrials |
| Diabetes Mellitus, Type 1 | 2 | D003922 | ClinicalTrials |
| Macular Degeneration | 1 | D008268 | ClinicalTrials |
| Arthritis, Psoriatic | 1 | D015535 | ClinicalTrials |
| Hidradenitis Suppurativa | 1 | D017497 | ClinicalTrials |
| Renal Insufficiency, Chronic | 1 | D051436 | ClinicalTrials |
Cross References
| Resources | Reference |
|---|---|
| CAS NUMBER | 214745-43-4 |
| ChEMBL | CHEMBL1201575 |
| FDA SRS | XX2MN88N5D |
| Guide to Pharmacology | 6593 |
CONTENTS